ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,484.00
0.01%
S&P ASX All Technology
4,027.90
0.88%
Brent Oil
76.445
0.68%
US Dollar vs AUD
1.59241
-0.15%
Bitcoin
98,163.50
0.70%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC

  6. Hemostemix Inc (QB) (HMTXF) Share Price

Hemostemix Inc (QB)

Hemostemix Inc (QB) (HMTXF)

USOTC
0.1864
0.0039
(2.14%)
Closed 11 February 8:00AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.1864
Bid
0.0001
Offer
1,200.29
Volume
17,800
0.1859 Day's Range 0.1899
0.024 52 Week Range 0.285
Market Cap
26.402M
Previous Close
0.1825
Open
0.1859
Last Trade
8200
@
0.1864
Last Trade Time
Financial Volume
US$ 3,345
VWAP
0.187894
Average Volume (3m)
58,431
Shares Outstanding
141,641,969
Dividend Yield
-
PE Ratio
-14.69
Earnings Per Share (EPS)
-0.02
Revenue
200k
Net Profit
-2.5M

About Hemostemix Inc (QB)

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) fro... Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced from the patient's blood. The Company is selling exempt compassionate treatments to individuals afflicted with critical limb ischemia, for example, and conducting clinical trials to commercialize its lead product, ACP-01, for the treatment of critical limb ischemia and peripheral arterial disease, and heart disease (ischemic cardiomyopathy, dilated cardiomyopathy). Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Website
www.hemostemix.com
Headquarters
Calgary, Alberta, Can
Founded
2014
Hemostemix Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker HMTXF. The last closing price for Hemostemix (QB) was US$0.18. Over the last year, Hemostemix (QB) shares have traded in a share price range of US$ 0.024 to US$ 0.285.

Hemostemix (QB) currently has 141,641,969 shares in issue. The market capitalisation of Hemostemix (QB) is US$25.85 million. Hemostemix (QB) has a price to earnings ratio (PE ratio) of -14.69.

Ask ADVFN Intelligence (AI)

HMTXF Latest News

More News

Financing & Partnership News Send Shares of this Stem-Cell Therapy Company on a Tear

While most stock indices are in the red today, shares of this pioneering stem cell firm are soaring following this morning's news of an LOI. In a press release this morning, Hemostemix Inc To read...

04 June 2024
AllPennyStocks.com

HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT

  HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT     May 10, 2021, Calgary, Alberta -- InvestorsHub NewsWire -- Hemostemix Inc...

11 May 2021
InvestorsHub NewsWire

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list

 Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list  Calgary, Alberta, April 23, 2021-- InvestorsHub NewsWire -- Hemostemix Inc. ("Hemostemix" or the...

26 April 2021
InvestorsHub NewsWire

Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates

  Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and  Litigation Updates   Calgary, Alberta, April 12, 2021-- InvestorsHub NewHemostemix Inc...

12 April 2021
InvestorsHub NewsWire

Hemostemix Announces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets Ltd.

Hemostemix Annonces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets LTD.   Calgary, Alberta, April 8, 2021 -- InvestorsHub NewsWire...

09 April 2021
InvestorsHub NewsWire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0136-6.80.20.210.1825436990.1989109CS
40.022914.0061162080.16350.2850.14928430.22614879CS
120.1315239.5264116580.05490.2850.0438584310.20770277CS
260.1496406.521739130.03680.2850.0301448490.15732807CS
520.1252204.5751633990.06120.2850.024319950.13805826CS
1560.068758.36873406970.11770.32790.024249980.15128262CS
2600.18153704.081632650.00490.43720.0049361390.09485196CS

HMTXF - Frequently Asked Questions (FAQ)

What is the current Hemostemix (QB) share price?
The current share price of Hemostemix (QB) is US$ 0.1864
How many Hemostemix (QB) shares are in issue?
Hemostemix (QB) has 141,641,969 shares in issue
What is the market cap of Hemostemix (QB)?
The market capitalisation of Hemostemix (QB) is USD 25.85M
What is the 1 year trading range for Hemostemix (QB) share price?
Hemostemix (QB) has traded in the range of US$ 0.024 to US$ 0.285 during the past year
What is the PE ratio of Hemostemix (QB)?
The price to earnings ratio of Hemostemix (QB) is -14.69
What is the cash to sales ratio of Hemostemix (QB)?
The cash to sales ratio of Hemostemix (QB) is 185.71
What is the reporting currency for Hemostemix (QB)?
Hemostemix (QB) reports financial results in CAD
What is the latest annual turnover for Hemostemix (QB)?
The latest annual turnover of Hemostemix (QB) is CAD 200k
What is the latest annual profit for Hemostemix (QB)?
The latest annual profit of Hemostemix (QB) is CAD -2.5M
What is the registered address of Hemostemix (QB)?
The registered address for Hemostemix (QB) is SUITE 1150, 707-7TH AVE SW, CALGARY, CALGARY, ALBERTA, T2P 3H6
What is the Hemostemix (QB) website address?
The website address for Hemostemix (QB) is www.hemostemix.com
Which industry sector does Hemostemix (QB) operate in?
Hemostemix (QB) operates in the BLANK CHECKS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NHHSNorthStar Healthcare Income Inc (PK)
US$ 1.00
(333,233.33%)
733
MJNEMJ Holdings Inc (CE)
US$ 0.0003
(29,900.00%)
80.55k
TTCMTautachrome Inc (CE)
US$ 0.0002
(19,900.00%)
1.48M
BRGOBergio International Inc (PK)
US$ 0.0001
(9,900.00%)
1.5M
TTCFQTattooed Chef Inc (CE)
US$ 0.0001
(9,900.00%)
47.19k
AAGRAfrican Agriculture Holdings Inc (CE)
US$ 0.000001
(-99.99%)
519
AGLYAtlantis Glory Inc (PK)
US$ 0.0018
(-99.91%)
2.5k
OGAAOrganic Agricultural Company Ltd (CE)
US$ 0.000001
(-99.80%)
6.2k
IVRNInnoveren Scientific Inc (CE)
US$ 0.000001
(-99.80%)
600
ELYSElys BMG Group Inc (CE)
US$ 0.000001
(-99.75%)
3.62k
HMBLHUMBL Inc (PK)
US$ 0.0005
(0.00%)
318.98M
ENDVEndonovo Therapeutics Inc (PK)
US$ 0.00025
(0.00%)
145.73M
VTXBVortex Brands Company (PK)
US$ 0.0001
(0.00%)
130.18M
SPQSSportsQuest Inc (PK)
US$ 0.0004
(0.00%)
130.05M
HCMCHealthier Choices Management Corporation (PK)
US$ 0.0001
(0.00%)
125.13M

HMTXF Discussion

View Posts
JamesMacho JamesMacho 1 year ago
Investors in $HEM are still waiting for any positive financial data to emerge, but so far, it's been a disappointing journey.
👍️0
tw0122 tw0122 2 years ago
Boom boom time
👍️0

Your Recent History

USOTC
HMTXF
Hemostemix (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads